List view / Grid view
4 January 2016 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells...
22 December 2015 | By
Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer...
11 December 2015 | By Victoria White
In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)...
1 December 2015 | By Victoria White
An official decision on the Ophran Drug Designation is expected from the European Commission in December...
26 November 2015 | By Victoria White
The EC has approved a label update to expand the use of Xalkori (crizotinib) to first-line treatment of adults with ALK-positive NSCLC...
25 November 2015 | By Garry White, Chief Investment Commentator, Charles Stanley
Viagra maker Pfizer announced on Monday that it would purchase Allergan, the Irish maker of Botox, for about $160bn – the biggest deal ever in the healthcare sector. Could more mega-mergers be in prospect?
23 November 2015 | By Victoria White
The combined company, to be named Pfizer plc, will be the biggest drug maker in the world by sales...
19 November 2015 | By Victoria White
Earlier this month, Great Ormond Street Hospital (GOSH) reported that UCART19 had been used treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia...
18 November 2015 | By Victoria White
Xalkori demonstrated significantly prolonged progression-free survival in previously untreated East Asian patients with ALK-positive advanced NSCLC...
18 November 2015 | By Victoria White
Avelumab (MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody...
4 November 2015 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body’s own immune system to fight cancer...
29 October 2015 | By Victoria White
Allergan has said that it is in preliminary “friendly discussions” with Pfizer regarding a potential business combination transaction...
19 October 2015 | By Victoria White
Pfizer’s investigational antibody-drug conjugate inotuzumab ozogamicin has received Breakthrough Therapy designation for acute lymphoblastic leukaemia...
8 October 2015 | By Victoria White
The designation relates to the clinical development programme for avelumab in metastatic MCC, which includes the Phase II study, JAVELIN Merkel 200...
24 September 2015 | By Victoria White
Sayana Press combines a long-acting, reversible, contraceptive with an all-in-one prefilled, single-use, non-reusable Uniject injection system...
